Dr. Karo K. Arzoo, MD

Dr. Arzoo practices at Socal Breathe Free ASC LLC in Burbank, California.

Dr. Arzoo's NPI, 1306862859, was assigned on July 15, 2006. Dr. Arzoo graduated from David Geffen School of Medicine at UCLA in 1996. Dr. Arzoo holds California license A64524.

Dr. Arzoo's primary practice is Socal Breathe Free ASC LLC, at 201 S Buena Vista St, Burbank, CA 91505 in Los Angeles County. The practice phone is (520) 979-6774.

Dr. Arzoo's primary practice is Socal Breathe Free ASC LLC in Burbank, California. Dr. Arzoo is also affiliated with Providence Saint Joseph Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Arzoo to 3 more hospitals, 1 group practice or clinic, 1 home health agency and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Arzoo practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Arzoo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Arzoo is board certified in hematology by the American Board of Internal Medicine. Dr. Arzoo is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and immune deficiency disease among the conditions Dr. Arzoo treats.

CMS data shows 42,034 Medicare services from Dr. Arzoo across 37 procedure codes in 2024, for 715 Medicare patients. Medicare paid $1,127,792 for them.

CMS counts 715 Medicare patients who saw Dr. Arzoo in 2024. The largest group is 65 to 74, with 310 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 43% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Arzoo's median patient age at 69, with 60% women.

In 2024, Dr. Arzoo wrote 2,952 Medicare Part D claims for 355 patients. 71% of them were for generic drugs. CMS names the drug for 2,430 of them, across 71 drugs with 11 or more claims each, at $7,348,242 in total drug cost. In 2023, CMS named 2,598 claims across 78 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Arzoo for performance year 2024, reported as part of a group. Dr. Arzoo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Arzoo as offering telehealth.

Dmand AI links 3 papers to Dr. Arzoo in 2020. The most frequent topics are Amino Acid Sequence, Histocompatibility Antigens Class II and Hybridomas. Dr. Arzoo has published most often in J Exp Med. Dr. Arzoo's most frequent co-authors are Maurice Julian Berkowitz, MD, David Chan, MD and Paul Herman Coluzzi, MD.

CMS Open Payments shows 77 general payments to Dr. Arzoo from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 69% of the total. Janssen Pharmaceuticals, Inc paid the most, $2,819.

Dr. Arzoo graduated from David Geffen School of Medicine at UCLA in 1996. Dr. Arzoo is a member of ASCO.

Dr. Arzoo is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.